Carvalho Ana Sofia, Ribeiro Helena, Voabil Paula, Penque Deborah, Jensen Ole N, Molina Henrik, Matthiesen Rune
From the ‡Proteolysis in Diseases, IPATIMUP, Institute of Molecular Pathology and Immunology of the University of Porto, Rua Dr. Roberto Frias s/n, 4200-465 Porto, Portugal; §Human Genetics Department, National Institute of Health Dr Ricardo Jorge, Av. Padre Cruz, 1649-016 Lisboa, Portugal;
From the ‡Proteolysis in Diseases, IPATIMUP, Institute of Molecular Pathology and Immunology of the University of Porto, Rua Dr. Roberto Frias s/n, 4200-465 Porto, Portugal;
Mol Cell Proteomics. 2014 Dec;13(12):3294-307. doi: 10.1074/mcp.M113.034363. Epub 2014 Aug 15.
We investigated the molecular effects of glucosamine supplements, a popular and safe alternative to nonsteroidal anti-inflammatory drugs, for decreasing pain, inflammation, and maintaining healthy joints. Numerous studies have reported an array of molecular effects after glucosamine treatment. We questioned whether the differences in the effects observed in previous studies were associated with the focus on a specific subproteome or with the use of specific cell lines or tissues. To address this question, global mass spectrometry- and transcription array-based glucosamine drug profiling was performed on malignant cell lines from different stages of lymphocyte development. We combined global label-free MS-based protein quantitation with an open search for modifications to obtain the best possible proteome coverage. Our data were largely consistent with previous studies in a variety of cellular models. We mainly observed glucosamine induced O-GlcNAcylation/O-GalNAcylation (O-HexNAcylation); however, we also observed global and local changes in acetylation, methylation, and phosphorylation. For example, our data provides two additional examples of "yin-yang" between phosphorylation and O-HexNAcylation. Furthermore, we mapped novel O-HexNAc sites on GLU2B and calnexin. GLU2B and calnexin are known to be located in the endoplasmic reticulum (ER) and involved in protein folding and quality control. The O-HexNAc sites were regulated by glucosamine treatment and correlated with the up-regulation of the ER stress marker GRP78. The occupancy of O-HexNAc on GLU2B and calnexin sites differed between the cytosolic and nuclear fractions with a higher occupancy in the cytosolic fraction. Based on our data we propose the hypothesis that O-HexNAc either inactivates calnexin and/or targets it to the cytosolic fraction. Further, we hypothesize that O-HexNAcylation induced by glucosamine treatment enhances protein trafficking.
我们研究了氨基葡萄糖补充剂的分子效应,氨基葡萄糖是一种广受欢迎且安全的非甾体抗炎药替代品,可减轻疼痛、炎症并维持关节健康。大量研究报告了氨基葡萄糖治疗后的一系列分子效应。我们质疑先前研究中观察到的效应差异是否与对特定亚蛋白质组的关注或特定细胞系或组织的使用有关。为了解决这个问题,我们对来自淋巴细胞发育不同阶段的恶性细胞系进行了基于全局质谱和转录阵列的氨基葡萄糖药物分析。我们将基于无标记质谱的全局蛋白质定量与开放的修饰搜索相结合,以获得尽可能好的蛋白质组覆盖范围。我们的数据在很大程度上与先前在各种细胞模型中的研究一致。我们主要观察到氨基葡萄糖诱导的O-连接的N-乙酰葡糖胺化/O-连接的N-乙酰半乳糖胺化(O-己糖胺化);然而,我们也观察到乙酰化、甲基化和磷酸化的全局和局部变化。例如,我们的数据提供了磷酸化和O-己糖胺化之间“阴阳”关系的另外两个例子。此外,我们在GLU2B和钙连蛋白上绘制了新的O-己糖胺位点。已知GLU2B和钙连蛋白位于内质网(ER)中,并参与蛋白质折叠和质量控制。O-己糖胺位点受氨基葡萄糖处理的调节,并与内质网应激标志物GRP78的上调相关。GLU2B和钙连蛋白位点上O-己糖胺的占有率在胞质和核部分之间有所不同,胞质部分的占有率更高。基于我们的数据,我们提出假设,即O-己糖胺要么使钙连蛋白失活和/或将其靶向胞质部分。此外,我们假设氨基葡萄糖处理诱导的O-己糖胺化增强了蛋白质运输。